Emory University: Multiple Myeloma trials
The registry lists 21 Multiple Myeloma studies with Emory University as lead sponsor. 3 are open to participants now and 7 have results posted.
Phase 1 9Phase 2 9Phase 4 2No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE TrialRecruitingNCT07101445Phase 4
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaRecruitingNCT05208307Phase 2
- Personalized Autologous Transplant for Multiple MyelomaRecruitingNCT04483206Phase 1
- Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell TransplantCompletedNCT05274763Not applicableResults posted
- Influenza Vaccination for Flu Prevention in Patients With Plasma Cell DisordersCompletedNCT04080531Phase 4Results posted
- Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT03267888Phase 1/2Results posted
- Evaluating Effectiveness of Powered Drill Bone Marrow BiopsyCompletedNCT03078452Not applicableResults posted
- Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 RearrangementCompletedNCT02765854Phase 2Results posted
- Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple MyelomaTerminatedNCT01969565Phase 2Results posted
- Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding StudyTerminatedNCT00793650Phase 1/2Results posted
- Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell TransplantationActive, not recruitingNCT06328699Not applicable
- Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple MyelomaActive, not recruitingNCT05391750Phase 1
- Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell TherapyWithdrawnNCT05204160Phase 2
- Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney FailureTerminatedNCT04352205Phase 2
- Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03942224Phase 2
- Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple MyelomaActive, not recruitingNCT03756896Phase 2
- Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple MyelomaCompletedNCT03605719Phase 1
- Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple MyelomaCompletedNCT01549431Phase 1
- A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT01485835Phase 1
- A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01038388Phase 1
- Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple MyelomaCompletedNCT00972712Phase 1